BillionToOne Issues 2026 Guidance with 40–45% Revenue Growth and Ongoing Profitability

BillionToOne has shared an update. The company has issued 2026 revenue guidance of $415 million to $430 million, implying year-over-year growth of approximately 40% to 45%, and indicated it expects to maintain positive GAAP operating income. Management links this outlook to demand for its diagnostic platform, which spans ultra-sensitive prenatal testing and advanced cancer diagnostics aimed at improving accessibility and accuracy.

For investors, the guidance signals expectations of strong top-line expansion coupled with ongoing operating profitability, a combination that is relatively uncommon among high-growth diagnostics firms. Sustained positive GAAP operating income suggests that BillionToOne may be achieving operating leverage as volumes scale, potentially reducing the need for near-term external capital and improving its path toward long-term value creation. The emphasis on both prenatal and oncology diagnostics positions the company in large, structurally growing markets, where continued product adoption and reimbursement support will be key to meeting the stated targets. If realized, the guidance could enhance BillionToOne’s competitive standing within the molecular diagnostics and precision medicine space and may strengthen its profile ahead of any future financing or strategic transactions. However, actual results will remain contingent on execution, regulatory and reimbursement environments, and competitive dynamics in the broader diagnostics industry.